Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000660544 | SCV000782650 | uncertain significance | Mucopolysaccharidosis type 6 | 2017-04-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000660544 | SCV002814421 | uncertain significance | Mucopolysaccharidosis type 6 | 2021-08-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000660544 | SCV004293556 | likely pathogenic | Mucopolysaccharidosis type 6 | 2024-01-12 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 310 of the ARSB protein (p.Asn310Asp). This variant is present in population databases (no rsID available, gnomAD 0.007%). This missense change has been observed in individual(s) with ARSB-related conditions (PMID: 28831385). ClinVar contains an entry for this variant (Variation ID: 547955). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSB protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |